Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Murine anti-CD3 (OKT3, Muromonab-CD3) is a potent human T-lymphocyte mitogen. A previous clinical Phase I trial examined OKT3 as an immunomodulator for the treatment of cancer. However, the murine monoclonal antibody triggered a potent humoral response that neutralized the antibody activity during subsequent administration. Thus, a "humanized" form of OKT3 (hOKT3gamma4) was developed to minimize immunogenicity. The genetically engineered human anti-CD3 retained its binding activity and effectively activated T cells in vitro. Therefore, we evaluated the safety and activity of hOKT3gamma4 in a Phase I clinical trial. hOKT3gamma4 was administered as a 10-min i.v. infusion every 2 weeks for three injections (one course of therapy). Six dose levels ranging from 50 to 1600 microg/injection were evaluated. Headache and fever were common, transient toxicities but were not dose limiting. The dose-limiting toxicities were rigors and dyspnea at the 1600-microg dose level, which defined 800 microg as the maximally tolerated dose in this trial. A dose-dependent in vivo T-lymphocyte activation was produced by this treatment, and the most significant T-lymphocyte activation occurred in patients treated at the two highest dose levels (800 and 1600 microg). Persistent CD3 modulation occurred after administration of 1600 microg of hOKT3gamma4. Anti-idiotypic antibodies were detected in only 6 of 24 patients after multiple injections and were not associated with attenuation of T-lymphocyte activation. Malignant ascites resolved in three patients, one each with peritoneal mesothelioma, pancreatic adenocarcinoma, and ovarian adenocarcinoma. hOKT3gamma4 can induce T-lymphocyte activation in patients with cancer, and the immunogenicity of the "humanized" antibody is sufficiently reduced relative to its murine "parent" to permit immunostimulation by repetitive i.v. administration. The therapeutic potential of biweekly i.v. hOKT3gamma4 at a dose of 800 microg should be further evaluated.
Richards
J
J
The Division of Hematology/Oncology, Lutheran General Hospital, Park Ridge, Illinois 60068, USA.
Auger
J
J
Peace
D
D
Gale
D
D
Michel
J
J
Koons
A
A
Haverty
T
T
Zivin
R
R
Jolliffe
L
L
Bluestone
J A
JA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000276:immunology; D001201:Ascites / Q000209:etiology / Q000628:therapy; D017252:CD3 Complex / Q000276:immunology; D004417:Dyspnea / Q000209:etiology; D005260:Female; D005334:Fever / Q000209:etiology; D006261:Headache / Q000209:etiology; D006801:Humans; D007167:Immunotherapy; D007262:Infusions, Intravenous; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008875:Middle Aged; D016853:Muromonab-CD3; D009369:Neoplasms / Q000150:complications / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D012449:Safety; D013045:Species Specificity; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D017252:CD3 Complex; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2; C118886:hOKT3 gamma4